Actual scientific article is at DOI:10.1158/1078-0432.CCR-18-4022.
Phase 1 prospective cohort trial with 15 enrolled patients undergoing primary resective surgery for non-muscle invasive bladder cancer. Primary endpoint is patient safety; they report no "significant toxicities" from therapy.
Secondary endpoint: evidence of tumor inflammation and viral changes. They show inflammation-related changes in treated patients and resolution of tumor in 1 out of 15 patients.
There's no comparison arm; clinically important measures of efficacy like progression-free survival and overall survival were not assessed. The major aim of the study is to justify phase II/III trials down the road.
COI: one of the authors has received funding from Viralytics and several other authors work for Viralytics. Viralytics funded the study.
There is no way a study like this should receive anything like the headline or coverage it's gotten. It is a phase 1 study only without clinically relevant efficacies reported and without a comparison arm. The power to detect uncommon but not even rare adverse effects is low.